White Blood Cell Ratios Predict Melanoma Patients' Survival
The ratio of neutrophils to lymphocytes – two types of white blood cells – can give oncologists valuable information regarding a patient’s prognosis.
BY Wayne Kuznar
PUBLISHED September 21, 2017
The ratio of neutrophils to lymphocytes – two types of white blood cells – can give oncologists valuable information regarding a patient’s prognosis. In fact, the neutrophil-to-lymphocyte ratio (NLR) was found to be an independent factor for overall survival (OS) in patients with metastatic melanoma, regardless of whether they received either targeted therapy or immunotherapy.
In a retrospective analysis, OS was markedly improved in patients with an NLR less than 5 at a median of 14.8 months compared with those who had an NLR greater than 5, in whom the median OS was five months, according to research presented by Elizabeth Blackley, M.D., at the 2017 European Society for Medical Oncology (ESMO) Congress.
“The interesting thing about NLR is that we expected it to be prognostic in immunotherapy—the context being immunogenic tumors,” said Blackley, Oncology Registrar, Olivia Newton-John Cancer Wellness and Research Center, Heidelberg Victoria, Australia, where the study was conducted. “The interesting thing in our study was that we found it was almost equally predictive in patients receiving targeted therapy. What it is actually showing is favorable biologic disease.”
An elevated NLR had already been shown to be a poor prognostic marker in many solid tumors, including melanoma. Previous literature had confirmed that NLR was a prognostic marker in patients with melanoma who were treated with Yervoy (ipilimumab) and predicted progression-free survival in patients treated with immune checkpoint inhibitors.
Blackley and colleagues sought to assess NLR as a marker of prognosis independent of traditional prognostic features in patients with metastatic melanoma receiving targeted therapy and immunotherapy.
They examined the utility of NLR as a prognostic factor in 152 patients with stage 4 melanoma who received at least one dose of first-line targeted therapy (74 patients) or immunotherapy (78 patients) from August 2010 to July 2017. Standard-of-care therapies were used in 55 percent of patients, which included a single-agent PD-1 inhibitor in 21.1 percent overall, a combination of PD-1/CTLA-4 inhibitor in 3.9 percent, and a combination of a BRAF- and MEK-targeted agents in 30.9 percent. Prior standard-of-care regimens were used in 45 percent (single-agent BRAF or MEK inhibitor in 17.8 percent and single-agent CTLA-4 inhibitor in 26.3 percent).
The baseline NLR was calculated from neutrophil and lymphocyte counts immediately prior to treatment. Median follow-up was 33 months, with only four patients lost to follow-up. NLR was analyzed and calculated in two categories for patients: more than or less than 5. A total of 104 (68 percent) patients had an NLR less than 5 and 48 (32 percent) had an NLR greater than 5.
When the results were stratified for those receiving current standard-of-care therapies versus superseded regimens, OS with standard-of-care regimens extended to 17.7 months, with follow-up ongoing.
When OS was broken down by agent received, an NLR less than 5 remained a strong indicator of favorable prognosis compared with NLR over 5 in patients treated with either targeted therapy or immunotherapy.
On multivariate analysis that included NLR, gender, melanoma stage, central nervous system metastases, liver metastases, level of lactate dehydrogenase (LDH) and age, NLR was the strongest predictor of OS.
The baseline ECOG performance status was documented in 119 of 152 patients (78 percent). Of these 119, (92 percent) had a performance score of 0 or 1, 6 percent were ECOG 2, and 2 percent were ECOG 3, making it unlikely that the results were confounded by a high proportion of patients with poor performance status.
When analyzed as a continuous variable, NLR remained significant as the most prognostic factor of OS. Multivariate analysis by treatment group confirmed NLR as the most significant predictive factor in patients receiving immunotherapy and second to LDH in targeted therapies.
The value of NLR may lie in selecting candidates for intensive treatment, said Blackley, whereas patients with a more favorable NLR may be candidates for single-agent PD-1 inhibition or dual BRAF-/MEK- targeted therapy or perhaps sequential rather than combination immunotherapy.